CN103553984A - 美索舒利晶型及其制备方法 - Google Patents
美索舒利晶型及其制备方法 Download PDFInfo
- Publication number
- CN103553984A CN103553984A CN201310476323.3A CN201310476323A CN103553984A CN 103553984 A CN103553984 A CN 103553984A CN 201310476323 A CN201310476323 A CN 201310476323A CN 103553984 A CN103553984 A CN 103553984A
- Authority
- CN
- China
- Prior art keywords
- mei suoshuli
- crystal formation
- crystal
- suoshuli
- mei
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 99
- 238000002360 preparation method Methods 0.000 title abstract description 12
- 238000002441 X-ray diffraction Methods 0.000 claims abstract description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 62
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- 239000003960 organic solvent Substances 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 18
- 238000002425 crystallisation Methods 0.000 claims description 15
- 230000008025 crystallization Effects 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 description 15
- 239000000243 solution Substances 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 9
- 239000012043 crude product Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 5
- 229960000965 nimesulide Drugs 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- MWIHBRBXESGTNB-UHFFFAOYSA-N COc(c([N+]([O-])=O)c1)ccc1Oc(cc(cc1)[N+]([O-])=O)c1NS(C)(=O)=O Chemical compound COc(c([N+]([O-])=O)c1)ccc1Oc(cc(cc1)[N+]([O-])=O)c1NS(C)(=O)=O MWIHBRBXESGTNB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000085 chronic toxic effect Toxicity 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- OBTVYILXIRNVAP-UHFFFAOYSA-N n-[2-(4-methoxyphenoxy)-4-nitrophenyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1OC1=CC([N+]([O-])=O)=CC=C1NS(C)(=O)=O OBTVYILXIRNVAP-UHFFFAOYSA-N 0.000 description 1
- MXLQIIYPGYSBSG-UHFFFAOYSA-N n-[2-(4-methoxyphenoxy)phenyl]methanesulfonamide Chemical compound C1=CC(OC)=CC=C1OC1=CC=CC=C1NS(C)(=O)=O MXLQIIYPGYSBSG-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 238000011020 pilot scale process Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310476323.3A CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310081069.7 | 2013-03-14 | ||
CN201310081069 | 2013-03-14 | ||
CN201310476323.3A CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103553984A true CN103553984A (zh) | 2014-02-05 |
CN103553984B CN103553984B (zh) | 2015-11-25 |
Family
ID=50008392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310476323.3A Expired - Fee Related CN103553984B (zh) | 2013-03-14 | 2013-10-11 | 美索舒利晶型及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103553984B (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016029495A1 (zh) * | 2014-08-29 | 2016-03-03 | 武汉光谷人福生物医药有限公司 | 美索舒利薄膜衣片 |
CN105384664A (zh) * | 2015-10-15 | 2016-03-09 | 中国药科大学 | 一种美素舒利新晶习 |
CN105434385A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利缓释片及其制备方法 |
CN105435239A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 微晶纤维素在美索舒利制剂中的用途、用于美索舒利的辅料、美索舒利制剂及其制备方法 |
CN105434378A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利分散片及其制备方法 |
CN105434392A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利胶囊及其制备方法 |
CN105434361A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利颗粒剂及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840594A (en) * | 1972-12-18 | 1974-10-08 | Gulf Research Development Co | Process for preparing mesitylenic acid |
CN1511828A (zh) * | 2002-12-31 | 2004-07-14 | �й������ž�����ҽѧ��ѧԺ����ҽ | 磺酰苯胺类衍生物及其医药用途 |
-
2013
- 2013-10-11 CN CN201310476323.3A patent/CN103553984B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3840594A (en) * | 1972-12-18 | 1974-10-08 | Gulf Research Development Co | Process for preparing mesitylenic acid |
CN1511828A (zh) * | 2002-12-31 | 2004-07-14 | �й������ž�����ҽѧ��ѧԺ����ҽ | 磺酰苯胺类衍生物及其医药用途 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016029495A1 (zh) * | 2014-08-29 | 2016-03-03 | 武汉光谷人福生物医药有限公司 | 美索舒利薄膜衣片 |
CN105434385A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利缓释片及其制备方法 |
CN105435239A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 微晶纤维素在美索舒利制剂中的用途、用于美索舒利的辅料、美索舒利制剂及其制备方法 |
CN105434378A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利分散片及其制备方法 |
CN105434392A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利胶囊及其制备方法 |
CN105434361A (zh) * | 2014-08-29 | 2016-03-30 | 武汉光谷人福生物医药有限公司 | 美索舒利颗粒剂及其制备方法 |
CN105434378B (zh) * | 2014-08-29 | 2018-07-03 | 武汉光谷人福生物医药有限公司 | 美索舒利分散片及其制备方法 |
CN105434392B (zh) * | 2014-08-29 | 2018-11-02 | 武汉光谷人福生物医药有限公司 | 美索舒利胶囊及其制备方法 |
CN105434361B (zh) * | 2014-08-29 | 2018-11-23 | 武汉光谷人福生物医药有限公司 | 美索舒利颗粒剂及其制备方法 |
CN105434385B (zh) * | 2014-08-29 | 2018-12-11 | 武汉光谷人福生物医药有限公司 | 美索舒利缓释片及其制备方法 |
CN105435239B (zh) * | 2014-08-29 | 2019-04-26 | 武汉光谷人福生物医药有限公司 | 美索舒利薄膜衣片及其制备方法 |
CN105384664A (zh) * | 2015-10-15 | 2016-03-09 | 中国药科大学 | 一种美素舒利新晶习 |
Also Published As
Publication number | Publication date |
---|---|
CN103553984B (zh) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103553984B (zh) | 美索舒利晶型及其制备方法 | |
CN105237571A (zh) | 9-[(r)-2-[[(s)-[[(s)-1-(异丙氧基羰基)乙基]氨基]苯氧基氧膦基]甲氧基]丙基]腺嘌呤的盐 | |
CN102558182B (zh) | 一种厄他培南钠晶型及其制备方法 | |
CN105524044A (zh) | 曲格列汀杂质及其组合物 | |
CN102766097B (zh) | 一种依达拉奉a型晶体及其制备方法 | |
CN105017218A (zh) | 一种右兰索拉唑晶型及其制备方法 | |
CN106916142A (zh) | 一种制备高纯度德拉沙星的方法 | |
CA2900705A1 (en) | Process for preparing atazanavir sulphate | |
CN102643234A (zh) | 依达拉奉多晶型物及其制备方法 | |
CN104402973A (zh) | 一种卡非佐米无定型晶的制备方法 | |
CN103539641B (zh) | 液晶化合物二氟-[(4-烷氧基-2,3,5,6-四氟苯基)乙基)-3,5-二氟苯基-3,4,5-三氟苯氧基]甲烷的合成方法 | |
CN103483334B (zh) | 盐酸戊乙奎醚外消旋体ii的晶型及其制备方法 | |
CN104277005A (zh) | 一种吉非替尼Form 1晶型的制备方法 | |
CN104496909A (zh) | 一种双核苯并咪唑离子盐及其制备方法和应用 | |
CN104211693A (zh) | 一种利伐沙班新晶型及其制备方法与用途 | |
CN102924448A (zh) | 生物碱cryptolepine类似物吲哚并喹啉酸化合物及制备方法 | |
RU2019106531A (ru) | Кристалл соли производного хиназолина | |
CN104844681B (zh) | 一种l晶型依普利酮的精制方法 | |
CN103804366B (zh) | 一种拉呋替丁晶型化合物 | |
CN103382179A (zh) | 英加韦林的多晶型物及其制备方法 | |
CN102267936A (zh) | 一种甲磺酸阿比朵尔晶型的制备方法 | |
CN103601702A (zh) | 一种盐酸洛美利嗪的制备方法 | |
CN103553985B (zh) | 一种4-甲氧基- n,n′-二取代苯基-1,3-苯二磺酰胺类化合物及其应用 | |
CN105111162A (zh) | 一种赛利司他新晶型及其制备方法 | |
CN102731388A (zh) | 一种(r)/(s)-6,6’-二羟基-5,5’-双喹啉的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20151028 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Applicant after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Address before: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666, room 718, humanwell Pharmaceutical Group Applicant before: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151208 Address after: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone, Road No. 666 humanwell Pharmaceutical Group Patentee after: WUHAN OPTICS VALLEY HUMANWELL BIO-PHARMACEUTICAL Co.,Ltd. Patentee after: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. Patentee after: HUMANWELL HEALTHCARE (GROUP) Co.,Ltd. Address before: The comprehensive office building of 430075 Hubei city of Wuhan province East Lake high tech Development Zone Road No. 666 humanwell Pharmaceutical Group Patentee before: HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151125 |